1Siegel RL, Miller KD, and Jemal A (2016) Cancer statistics. CA Cancer J Clin 66: 7-30.

2Hanker LC, Loibl S, Burchardi N, Pfisterer J, et al. (2012) The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 23: 2605-2612.

3Zou W, and Chen L (2008) Inhibitory B7-family molecules in the tumor microenvironment. Nature reviews. Immunology 8: 467-477.

4Keir ME, Butte MJ, Freeman GJ, and Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annual review of immunology 26: 677-704.

5Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, and Lopci E (2017) Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. European journal of nuclear medicine and molecular imaging 44: 2310-2325.

6Gaillard SL, Secord AA, and Monk B (2016) The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract 3: 11.

7Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria JC, and Marabelle A (2016) Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Ann Oncol 27:214-224.

8Barbee MS, Ogunniyi A, Horvat TZ, and Dang TO (2015) Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 49: 907-937.

9Boland JL, Zhou Q, Martin M, Callahan MK, Konner J, O'Cearbhaill RE, Friedman CF, et al. (2019) Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. Gynecol Oncol 152: 251-258.

10Varki A (2007) Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 110: 1723-1729.

11Khorana AA (2010) Venous thromboembolism and prognosis in cancer Thromb Res 125: 490-493.

12Kasthuri RS, Taubman MB, and Mackman N (2009) Role of tissue factor in cancer. J Clin Oncol 27: 4834-4838.

13Han LY, Landen CN, Jr, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, and Sood AK (2006) Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 24: 755-761.

14Satoh T, Oki A, Uno K, Sakurai M, Ochi H, Okada S, Minami R, et al. (2007) High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer 97: 1053-1057.

15Ebina Y, Uchiyama M, Imafuku H, Suzuki K, Miyahara Y, and Yamada H (2018) Risk factors for deep venous thrombosis in women with ovarian cancer. Medicine 97, e11009.

16Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandala M, Brighenti M, Petrelli F (2011) Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 9, 179.

17Nierodzik ML, and Karpatkin S (2006) Thrombin induce tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer cell 10: 355-362.

18Falanga A, Panova-Noeva M, and Russo L (2009) Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol 22: 49-60.

19Labelle M, Begum S, and Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer cell 20: 576-590.

20Ossovskaya VS, and Bunnett NW (2004) Protease-activated receptors: contribution to physiology and disease. Physiol Rev 84: 579-621.

21Danckwardt S, Hentze MW, and Kulozik AE (2013) Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. Journal of molecular medicine (Berlin, Germany) 91: 1257-1271.

22Degen JL, and Palumbo JS (2012) Hemostatic factors, innate immunity, and malignancy. Thromb Res 129 Suppl 1, S1-5.

23Queiroz KC, Shi K, Duitman J, Aberson HL, Wilmink JW, et al. (2014) Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. Int J Cancer 135: 2294- 2304.

24Adams GN, Rosenfeldt L, Frederick M, Miller W, Waltz D, Kombrinck K, McElhinney KE, (2015) Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen. Cancer Res 75: 4235-4243.

25Kopp HG, Placke T, and Salih HR (2009) Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 69: 7775-7783.

26Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW(2005) Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105: 178-185.

27Alexander ET, Minton AR, Peters MC, van Ryn J, and Gilmour SK (2016) Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment. Oncotarget 7: 85291-85305.

28Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, and Wienen W (2002) Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 45: 1757-1766.

29Guo Z, Wang X, Cheng D, Xia Z, Luan M, and Zhang S (2014) PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One 9, e89350.

30Ahmed N, and Stenvers KL (2013) Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol 3: 256.

31Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan R L, et al. (2015) Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol 35 Suppl, S185-S198.

32Danckwardt S, Gantzert AS, Macher-Goeppinger S, Probst HC, Gentzel M, et al. (2011) p38 MAPK controls prothrombin expression by regulated RNA 3' end processing. Mol Cell 41: 298-310.

33Levi M, van der Poll T, and Buller HR (2004) Bidirectional relation between inflammation and coagulation. Circulation 109: 2698-2704.

34Levi M, and van der Poll T (2010) Inflammation and coagulation. Crit Care Med 38: S26-34.

35Vergnolle N (2000) Proteinase-activated receptors - novel signals for gastrointestinal pathophysiology. Aliment Pharmacol Ther 14: 257-266.

36Grabosch S, Bulatovic M, Zeng F, Ma T, Zhang L, Ross M, Brozick J, Fang Y, Tseng G, et al. (2019) Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles. Oncogene 38: 2380-2393.

37Curran MA, Montalvo W, Yagita H, and Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America 107: 4275-4280.

38Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114: 1537-1544.

39Pollack CV, Jr. Reilly P A, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. (2017) Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med 377: 431-441.